![]() |
|
|
Vol. 296, Issue 2, 520-527, February 2001
Department of Pharmacology and Toxicology, College of Pharmacy
(D.E.C., G.R.H., K.A.K.), and Department of Psychology (R.P.K.),
University of Utah, Salt Lake City, Utah
The abuse of psychostimulants, such as methamphetamine (METH), can
cause long-lasting deficits in the dopamine (DA) innervation of the
striatum. Although the consequences of large DA depletions on basal
ganglia function have been well characterized, less is known about the
alterations associated with smaller depletions, such as those produced
by high doses of METH. The purpose of this study was to assess the
long-term consequences of METH-induced DA depletion on basal ganglia
function. Three weeks after rats were given multiple administrations of
METH (5-10 mg/kg, four times at 2-h intervals), dose-related decreases
in DA tissue content in striatum and tyrosine hydroxylase mRNA in the
substantia nigra pars compacta were observed. In situ hybridization
histochemistry revealed a selective decrease in preprotachykinin mRNA
in striatum, predominately at the highest dose of METH, and no change
in striatal preprodynorphin, preproenkephalin, or
neurotensin/neuromedin N mRNAs. Cytochrome oxidase activity was
significantly elevated in the entopeduncular nucleus and substantia
nigra pars reticulata of METH-treated rats, but not in the striatum,
globus pallidus, or subthalamic nucleus, consistent with a selective
decrease in striatonigral, but not striatopallidal, neuron function.
Additionally, rats treated with a neurotoxic regimen of METH were
impaired on a radial maze sequential learning task when tested 3 weeks
following METH administration. These data indicate that exposure to a
neurotoxic regimen of METH results in long-term changes in
striatonigral, but not striatopallidal neuron function and,
consequently, altered basal ganglia function.
This article has been cited by other articles:
![]() |
T. E. Nordahl, R. Salo, Y. Natsuaki, G. P. Galloway, C. Waters, C. D. Moore, S. Kile, and M. H. Buonocore Methamphetamine Users in Sustained Abstinence: A Proton Magnetic Resonance Spectroscopy Study Arch Gen Psychiatry, April 1, 2005; 62(4): 444 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Mark, J.-J. Soghomonian, and B. K. Yamamoto High-Dose Methamphetamine Acutely Activates the Striatonigral Pathway to Increase Striatal Glutamate and Mediate Long-Term Dopamine Toxicity J. Neurosci., December 15, 2004; 24(50): 11449 - 11456. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. CADET, S. JAYANTHI, and X. DENG Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis FASEB J, October 1, 2003; 17(13): 1775 - 1788. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Xie, L. Tong, T. Barrett, J. Yuan, G. Hatzidimitriou, U. D. McCann, K. G. Becker, D. M. Donovan, and G. A. Ricaurte Changes in Gene Expression Linked to Methamphetamine-Induced Dopaminergic Neurotoxicity J. Neurosci., January 1, 2002; 22(1): 274 - 283. [Abstract] [Full Text] [PDF] |
||||